Huntington's Disease: New Frontiers in Therapeutics

Purpose of ReviewThis article describes and discusses new potential disease-modifying therapies for Huntington's disease that are currently in human clinical trials as well as promising new therapies in preclinical development.Recent FindingsMultiple potential disease-modifying therapeutics for HD are in active development, including direct DNA/gene therapies, RNA modulation, and therapies targeted at aberrant downstream pathways.SummaryThe etiology of Huntington's disease (HD) is well-known as an abnormally expanded trinucleotide repeat within the huntingtin gene. However, the pathogenesis downstream of the mutant huntingtin gene is complex, involving multiple toxic pathways, including abnormal protein fragmentation and neuroinflammation. The current treatment of HD focuses largely on symptomatic management. This article discusses new, potential disease-modifying therapies that are currently in human clinical trials and preclinical development.

Automated summary

The article discusses new potential disease-modifying therapies for Huntington's disease that are currently being tested in human clinical trials and in preclinical development. These therapies include DNA/gene therapies, RNA modulation, and targeting abnormal downstream pathways, showing promise in addressing the complex pathogenesis of the disease.